Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
Lilly Endowment Inc. filed a Form 144 to sell 305,000 shares of Eli Lilly and Company (LLY) common stock, with an approximate sale date of November 12, 2025. The designated broker is J.P. Morgan Securities LLC, and the filing lists NYSE, NASDAQ as the exchanges.
The notice also details recent activity: examples include 300,000 shares sold on November 3, 2025 for $266,648,940 and 283,131 shares sold on November 11, 2025 for $279,347,662.01. The shares to be sold trace back to an earlier acquisition noted as a gift dated February 10, 1948 from the J.K. Lilly Sr. Trust.
Eli Lilly (LLY) CEO David A. Ricks reported a code G transfer of 24,750 shares of common stock on 11/10/2025 at a stated price of $0. Following the transaction, he directly owns 515,166.167 shares.
He also reports indirect holdings, including 6,685 shares by the David A. Ricks 2025 GRAT, 54,117 shares by the 2022 GRAT, 300 shares by a trust, 68,656 shares by the David A. Ricks SLAT, and 7,305.09 shares in a 401(k). The footnotes note a transfer of 6,685 shares to the 2025 GRAT on September 9, 2025.
Eli Lilly (LLY) officer (EVP, CS&PO & Pres. LRL) reported a Code G transaction of 179 shares of common stock on 11/10/2025 at a reported price of $0.
Following the transaction, the officer beneficially owned 137,481.112 shares directly. Indirect holdings were reported as 72,359 shares by a trust, 547 shares by a spouse, and 2,710 shares by a spouse’s SLAT, subject to a standard pecuniary interest disclaimer.
The filing notes a 200‑share correction to reconcile these holdings with a submission filed on August 12, 2025.
Lilly Endowment Inc. filed a Form 144 indicating a proposed sale of 300,000 shares of Eli Lilly and Company common stock, with an aggregate market value of $277,311,000. The filing lists Fidelity Capital Markets as broker, an approximate sale date of 11/10/2025, and the securities exchange as NYSE, NASDAQ.
The shares to be sold were originally acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust (donor acquisition date 01/21/1937). The notice also reports recent sales by Lilly Endowment Inc. over the past three months, including 300,000 shares on 11/03/2025 for $266,648,940 and 351,015 shares on 10/01/2025 for $284,653,451.48.
Eli Lilly, through its wholly owned subsidiary Flying Tigers Acquisition Corporation, launched a cash tender offer to acquire all outstanding shares of Adverum Biotechnologies (ADVM). Holders who tender will receive $3.56 per share in cash, plus one non‑tradable contingent value right (CVR) per share that entitles the holder to receive up to an aggregate $8.91 in contingent cash payments upon achievement of specified milestones, all subject to the terms and conditions of the CVR agreement and the Offer to Purchase.
The consideration is payable in cash, without interest and less applicable tax withholding, and the CVR provides potential added payments tied to future milestone achievements.
Lilly Endowment Inc., a reporting person for Eli Lilly and Company (LLY), reported multiple open‑market sales of common stock on 11/05/2025, totaling 40,432 shares across eight transactions coded “S.”
The trades executed at weighted‑average prices with ranges disclosed from $947.18 to $955.41. Following these transactions, the reporting person beneficially owned 93,711,978 shares with direct ownership.
Eli Lilly & Co (LLY): A reporting person identified as a director and 10% owner reported open‑market sales of common stock on 11/05/2025 across 30 separate transactions. The trades were executed at weighted‑average prices disclosed by tranche, with individual price ranges noted in the footnotes.
Following these sales, the reporting person directly beneficially owned 93,752,410 shares. The footnotes show sale price ranges spanning from $910.90 to $947.06 per share across the listed tranches. The remark states this is the first of two Forms 4 filed the same day, covering transactions #1–#30 of 38 total.
Lilly Endowment Inc., a director of Eli Lilly (LLY), reported selling 526 shares of common stock on 11/04/2025 with transaction code S. The sale was executed at a weighted average price of $910.719.
The shares were sold in multiple trades at prices ranging from $910.59 to $911.00. After this transaction, the reporting person beneficially owned 93,931,452 shares, held directly.
Lilly Endowment Inc., a director of Eli Lilly (LLY), reported open‑market sales totaling 300,000 shares of common stock on 11/03/2025.
The trades were executed in multiple tranches at weighted average prices with reported ranges from $877.00 to $901.295 per share, as detailed in footnotes. Following these transactions, the reporting person beneficially owned 93,931,978 shares directly.
Lilly Endowment Inc. filed a Form 144 notice to sell up to 220,000 shares of Eli Lilly and Company (LLY) common stock, reflecting an aggregate market value of $197,236,600. The filing lists J.P. Morgan Securities LLC as broker and an approximate sale date of 11/04/2025.
Shares outstanding were 945,383,757. The Endowment reports prior sales in the last three months, including 351,015 shares on 10/01/2025 for $284,653,451.48 and 300,000 shares on 11/03/2025 for $266,648,940. The securities trace back to a historical gift acquisition from the J.K. Lilly Sr. Trust.